Evaxion Biotech与MSD达成疫苗许可协议
根据协议条款，Evaxion授予MSD独家许可其疫苗候选物EVX-B2和EVX-B3的选择权。EVX-B2旨在预防淋病，而EVX-B3则针对一种未披露的传染因子。Evaxion将获得320万美元的预付款，如果MSD在2025年行使其许可选择权，Evaxion可能获得高达1000万美元。此外，Evaxion每种产品可能获得高达5.92亿美元的里程碑付款，外加净销售额的特许权使用费。
Evaxion stock jumps on expanded vaccine development pact with MSD
Evaxion Biotech (EVAX) shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its ...
FierceBiotech5 天
Merck bags options on Evaxion's AI-designed vaccines, offering small upfront and big back end
Merck & Co. has picked up options on two Evaxion vaccine candidates, paying $3.2 million and dangling more than $1 billion in ...
H.C. Wainwright维持Evaxion股票买入评级，引用AI驱动的癌症疫苗前景良好
H.C. Wainwright在周五维持了对Evaxion Biotech (NASDAQ:EVAX)股票的买入评级和14.00美元的目标价。这是在该公司于2024年9月16日在欧洲医学肿瘤学会(ESMO)年度大会上公布了其癌症疫苗候选药物EVX-01与pembrolizumab联合治疗不可切除/转移性黑色素瘤的2期研究一年随访数据之后。 数据显示，联合治疗的客观响应率(ORR)为69%，并展示了 ...
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Evaxion Biotech A/S (NASDAQ:EVAX) inked an option and licensing deal with Merck & Co., Inc (NYSE:MRK) for two preclinical ...
Evaxion Biotech Gains Buy Rating Amid Merck Collaboration and AI-Driven Vaccine Development ...
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Evaxion Biotech (EVAX – Research Report). The ...
The Pharma Letter5 天
Evaxion significantly expands vaccine deal with MSD
Danish clinical-stage AI-based vaccine developer Evaxion Biotech (Nasdaq: EVAX) has entered into an option and license ...
Evaxion significantly expands vaccine development collaboration with MSD
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a ...
Yahoo Finance5 天
Evaxion significantly expands vaccine development collaboration with MSD
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on ...